Parliament Workbench
Data: Official Report to 19 Nov 2026

Official Report · Committee

Continued Petitions

Ocular Melanoma (MRI Scans) (PE1629)

Thursday 26 September 2019 Public Petitions Committee About 09:30–10:15 Petitions 59 contributions · 6 speakers

Speakers

Choose an MSP to read only their contributions

The record

59 contributions
Gail Ross SNP The Deputy Convener · Caithness, Sutherland and Ross
link

Our next petition for consideration is PE1629, on magnetic resonance imaging scans for ocular melanoma sufferers in Scotland. The petition was lodged by Jennifer Lewis.

Last time we considered the petition, in January 2019, we took evidence from the Cabinet Secretary for Health and Sport. During the evidence session, the cabinet secretary stated that there was no clinical consensus across the UK on the use of MRI scans following an ocular melanoma diagnosis. In order to build greater clinical consensus in the area, a Scottish group for consensus on metastatic surveillance for uveal melanoma was established, and the group published its findings in a report in August. The work has been led by Dr Paul Cauchi, consultant ophthalmologist and lead for the Scottish ocular oncology service at Gartnavel general hospital, and he joins us today.

Thank you for attending, Dr Cauchi. I invite you to make a brief opening statement of no more than five minutes, after which we will move on to questions.

Dr Paul Cauchi Scottish Ocular Oncology Service
link

Thank you for inviting me to give evidence to the committee. Eye melanoma is a rare cancer, but it is absolutely a very important condition. Our service in Scotland takes the condition very seriously and the support of our patients is something that we care a lot about.

First, I would like to clear up something that has, I think, been unclear from the beginning. The premise of the petition is that there is a difference between Scotland and the rest of the UK. I have to disagree with that. There is a problem in the UK with a consensus as to how surveillance should be undertaken, but that is not a Scottish issue; it is a UK one. I would like to make that very clear.

I tried for many months to engage the other three ocular oncology centres in the UK—in Sheffield, London and Liverpool—to try to get a UK-wide consensus, because that is the best way forward to provide clarity for our patients. Unfortunately, I was not able to get engagement from the other three centres. I do not know why, but that is the situation that I faced. I therefore felt that we needed to press ahead in Scotland and come up with our own consensus statement, which I suspect will have quite an influence on the rest of the UK and perhaps further afield.

The statement group had representation from patients. We had a patient representative—Ronnie Blair from Scotland. We also had an English oncologist, who is a general cancer specialist—not just an eye cancer specialist—with an interest in eye cancer, three Scottish oncologists, an English ocular oncologist, two Scottish pathologists, two Scottish radiologists, me, and my colleague Vikas Chadha.

09:45

This was not an attempt to draw up guidelines, but an attempt to bring together a consensus statement. That is an important point, because we already have guidelines from 2015 that we cannot override. Our work has to complement those guidelines, if you like. The problem with the guidelines from 2015 is that they were left quite vague because the group could not agree on a protocol that all the centres could follow. The main reason for the disagreement was the lack of evidence and consensus.

The recommendation from those guidelines was that a non-ionising form of radiation be used to image the liver every six months. That is a vague statement. The two forms of non-ionising radiation are ultrasound and MRI scanning. We needed to try to clarify that statement for our patients in Scotland. Unfortunately, despite an updated review of the literature from 2015 that takes account of the four years since then, there is still a lack of evidence that MRI surveillance alters life expectancy for our patients with eye melanoma. Furthermore, there is no curative treatment for patients who develop spread of this type of cancer. Although there are lots of new and exciting treatments, the evidence is still—unfortunately—lacking that any of them make a difference.

There are, however, many exciting clinical trials. We are very excited about them and we want to be at the forefront of allowing our patients to access them. The Beatson unit, which is in the building next to where I work, is very much part of that.

The group decided to adopt a risk-stratified approach. I have read most of the Public Petitions Committee’s previous discussions about the petition, and in one of the discussions it was suggested that we are unable to stratify risk in Scotland. I absolutely refute that. Every single one of our patients has a risk attached to their tumour, and it is not correct to say that we have to have a biopsy to have that risk stratification. There is a very accurate way of stratifying risk based on size and location of tumour, so we know the risk of all our patients who come through in Scotland.

One of the main drivers is that we want to allow our patients to access the clinical trials. We decided that we would adopt a high-risk/low-risk strategy where the high-risk patients would be offered MRI scanning every six months and the low-risk patients would continue as at present, getting liver ultrasound and then going on to MRI scanning if required. There is no risk-free aspect to this. MRI scanning has many risks, which I might discuss later.

We feel that we have reached as far as we can with a group of clinicians and a patient representative to try to come up with a pragmatic approach for our patients in Scotland and to allow our high-risk patients to access the exciting clinical trials that are coming online, and also the liver-directed and systemic treatments that are available for them. I feel that the consensus statement is a real step forward in clarifying the situation for our patients. At least we in Scotland will be able to say that this is the line in the sand for our patients.

The report has been approved by the national services division in Scotland. It has been circulated to all the health board chief executives around the country, and it is now up to the boards to decide how they are going to implement the protocol—the statement. Thank you.

Gail Ross SNP The Deputy Convener · Caithness, Sutherland and Ross
link

Thank you for your very useful opening statement. You mentioned—and we have previously heard from the chief medical officer about—the lack of clinical consensus across the UK on the use of MRI scans. What do you think is the reason for that?

Dr Cauchi
link

It is interesting. Dr Ottensmeier, who was quoted a lot in the group, is a passionate advocate of MRI scanning. However—this is why medicine is such fun—we also have Paul Nathan, who is an eminent oncologist at Mount Vernon hospital. He was part of our group—he was also part of the original guidelines group in 2015—and he has completely the opposite view.

The fact that we can do something does not mean that we should do it. No one is disputing that an MRI scan of the liver is able to image the liver in a more accurate way than a liver ultrasound can but, in a way, that is not what is important for patients. What is important for patients is whether it will make a difference to their quality of life and their life expectancy, and there is absolutely no evidence for that.

An MRI scan is not a trivial thing. It takes 45 minutes to an hour to do a scan, and it is a pretty unpleasant experience, as you will hear if you speak to patients about it. Some of you might have had an MRI scan. My wife certainly has. It is pretty unpleasant for someone who is claustrophobic. There is some debate as to whether the contrast that is given can accumulate in the brain. That is another aspect, but the jury is out on that. There is also the anxiety that an MRI scan creates in the build-up and while the person is waiting for the report to come out afterwards. It is much harder to get an MRI scan, so it is likely that there will be some delay involved in trying to get one, and there will almost certainly be some delay in getting the report. It is very hard to get MRI scan reports in Scotland at present. Patients are waiting for their reports: they are phoning in every day to my unit and others. People speak about MRI scans as if they are easy and simple things to do, but they are not. They are a big undertaking and they can create a huge amount of anxiety.

The other thing is that MRI scanners are not available everywhere in the country. If someone lives in Lewis or on one of the islands, they might have access to an ultrasound but not to an MRI scan. The other day, I had a patient who would have to travel to Aberdeen to get an MRI scan, whereas they could get an ultrasound scan locally on their island. That is an example.

Doctors like evidence. We like to be directed by evidence. The reason why we get polar opposites is that there is a gap in the evidence. The problem with a rare disease is that it is very hard to get evidence on it, although that does not mean that we do not try to push to get as much as we can for our patients. I think that the bottom line is that with a lack of evidence comes almost a personal opinion of what should be done. We should try to get away from personal opinions and emotion and try to help our patients in a factual, evidence-based way. Many of my patients say to me, “Is this going to make a difference?” That is really what counts. I return to what I said: the fact that we can do something does not mean that we should do it. It is important that we use investigations in an appropriate manner.

In other countries such as America, people get a lot of investigations, and there are many reasons why they may or may not get investigations. That creates two things. First, it creates a financial and economic conveyor belt, and secondly, for the patient, it can open up a can of worms. False positive results in scanning are very common. If we scan a liver, we will find a lot of things in it. We will find cysts and haemangiomas—we will find all sorts of things—and that often leads to further investigations. It may lead to biopsies, and we are then going down a road that can almost cause more harm than the investigation itself.

I try to give the other side of the coin. Sometimes, it seems very easy and people say, “Why don’t you do MRI scans for everyone?” There are reasons why we do not do that. I will leave it there.

Brian Whittle Con South Scotland
link

Good morning, Dr Cauchi, and thank you for coming. The consensus group contained just one patient representative. How, if at all, did their involvement influence the group’s proceedings and thoughts?

Dr Cauchi
link

It was very valuable to have Ronnie Blair there. He is one of our patients and he is also a member of OcuMel UK, which is one of the patient pressure groups. He is a very balanced individual. He has his own personal journey. I do not think that I need to go into that, but he had a profound influence on the group. Like any group, we had a lot of debate, especially among the oncologists—not the eye cancer specialists, but the general cancer specialists who have an interest in eyes, as opposed to me, because I have an eye cancer interest. We had a lot of disagreement among the people in our group. I always think that that is a great thing, because if we are going to have a consensus group, we do not want everyone to be thinking in the same way; we want a balanced approach.

It was great having Ronnie there, because he could say, “Hang on—this is what’s important from my point of view.” He was excellent. We chose him for that reason, because we knew that he was going to bring a lot of quality to the group, and he had a big impact on it. I think that, at the end of the process, he realised that we had reached quite a pragmatic decision. We probably did not reach the decision that he wanted, but I think that we reached a decision that we could all be happy with.

Believe me—there was so much heated debate, and not all of the names would be here if we had not agreed. There was a time when we thought that we were going to lose a few people who would not give their agreement to the consensus group. The group was well run, there was robust debate, and we gave our patient representative a lot of time and a lot of influence over the proceedings.

Brian Whittle Con South Scotland
link

If his impact was as helpful as you say, was there any discussion about engaging with other patients in the same situation?

Dr Cauchi
link

Are you asking whether we should have involved other patients in the group?

Dr Cauchi
link

We decided to have one patient representative. There was no conspiracy about that—

Dr Cauchi
link

It was just the way that we set it up. I do not know what a minimum requirement would be for the number of patients on a group, but he was a good fit because he is one of our patients, he is Scottish and he is involved in OcuMel UK. He ticked a lot of boxes from that point of view, and he was prepared to come. Many patients would find this kind of thing quite daunting. I do not think that we deliberately had just one representative to dilute the impact.

Brian Whittle Con South Scotland
link

I was not suggesting for one second that that was the case. Thank you.

Gail Ross SNP The Deputy Convener · Caithness, Sutherland and Ross
link

Dr Cauchi, since our papers were circulated, we have received two written submissions from Iain Galloway and OcuMel UK. The joint position paper on MRI surveillance that has been compiled with melanoma patient network Europe and OcuMel UK indicates how they would like the issues that the petition raises to be resolved. I will bring one part to your attention and I ask you to respond to it. The paper says:

“The Scottish Guidelines Group did not seek patient representation from either OcuMel UK or Melanoma Patient Network Europe.”

Is that a true statement?

Dr Cauchi
link

That is incorrect. Ronnie Blair is a member of OcuMel UK. We did not get a representative from the Europe group, though.

Gail Ross SNP The Deputy Convener · Caithness, Sutherland and Ross
link

Okay. Thank you for that clarification.

Maurice Corry Con West Scotland
link

You touched on consensus and the Sheffield, London, Liverpool and Glasgow centres not coming together in relation an unwillingness to develop a consistent approach to the issue. Why do you think that they did not stitch together?

Dr Cauchi
link

I am not sure, to be honest, because those people are my friends and colleagues and I know them well. I think that the statement will have a very big impact, and if it is taken up in England, it will have a big impact on them, too. Of course, they have a different health service and different ways of commissioning, imaging and all the rest of it, and it could become quite an issue for them. Maybe that is part of the reason. It is difficult to second-guess them.

10:00

Sometimes people do not want to open the can of worms, because they are not sure where it is all going to lead. I like clarity. If patients have a problem or an issue, I think that it is terrible for them to have different experiences depending on where they go. What happens in England is a lot less regulated than what happens in Scotland, mainly because the population is much bigger. In England, you will get your eye cancer diagnosed and treated by an eye specialist. Then, if you are unfortunate enough to develop a metastatic issue in the liver, you will be referred to an oncologist. The eye cancer specialist will have washed their hands of that patient from the liver point of view—they will have gone on to another specialist.

Some centres will have a very good integrated multidisciplinary team set-up, but others may not. In fact, you can imagine all the geographic areas in London and all the clinical oncologists who cover all those areas, and we have spoken about Dr Ottensmeier in Southampton and Dr Nathan in Mount Vernon—and there are many, many others, too. They cannot all come to the MDT; that is not practical. If you go to Dr Nathan, you will get a liver ultrasound; if you go to Dr Ottensmeier, you will get an MRI scan; and if you go to someone else, you might get one treatment if you are high risk and another if you are low risk. In other words, there is a whole variety in what goes on.

In Scotland, we have a much tighter picture, mainly because of the size of the population, I suppose. Therefore, we had a fighting chance of trying to get a consensus for this country and for our patients. Maybe in England, it is a much harder task because of the population issue. If I was one of the English oncologists, I would welcome the consensus and I would want to be on the group, but I tried multiple times and at every turn, it was a negative. Unfortunately, I cannot do very much about that.

Maurice Corry Con West Scotland
link

In Scotland, you can plough ahead, on the basis of what you talked about, because you feel that we are more together up here—which is good news; that is great. Do you feel that we are missing out on anything by not having the UK group consensus?

Dr Cauchi
link

Absolutely.

Dr Cauchi
link

We are missing out because Scotland is not an isolated community and we speak to other patients in the UK. In fact, I think that we will have a reversal: English patients will be pretty unhappy that Scottish patients are going to get MRI scans for high risk while they are not. That is unsatisfactory because there are only 450 patients a year who get melanoma in the UK. It is a very small group of patients, and we feel very united as a UK group. In Scotland, we have, on average, about 40 patients a year—it is between 30 and 50 patients a year. We meet regularly, we meet our English counterparts and we compare our results. We are very much united.

This will be a situation where Scotland is going off on its own—in, I think, a good, positive way. However, not having the UK on board and not having the English centres on board is unfortunate, because it will pit us against them, which is not something that I want. I want all patients in the UK to feel that they are getting a standard of care and I do not think that that will happen because of the non-engagement of the English centres.

Maurice Corry Con West Scotland
link

So, if we look just at Scotland, we will not lose out and the quality of our medical support will not be depleted because we cannot get an agreement with the rest of the UK.

Dr Cauchi
link

No—I think the opposite.

Dr Cauchi
link

I think that more patients are going to get MRI scans in Scotland because of the consensus than will be the case in England.

David Torrance SNP Kirkcaldy
link

Do you agree with the petitioner’s concerns that, because ocular melanoma is so rare, there is a lack of understanding among the medical professions about the condition and the risks associated with it?

Dr Cauchi
link

I have to respectfully disagree with that. The condition is our passion—it is what I dedicate my life to. The idea that I do not take it seriously because it is a rare cancer is not correct. There is an interesting point, however, as there are similarities with conditions such as colorectal cancer, because the organ of spread of disease from the colon and the rectum is often the liver—although it is not just the liver; it can be other organs as well. When considering colorectal cancer, how do you image the liver, how often and so on? There are a lot of treatments for colorectal cancer that are a lot better and more effective than those for our cancer. However, most centres only image the liver for five years and then they stop. They do not use MRI; they use computed tomography and ultrasound. There are also varying opinions on what to do in colorectal, but it is a very common cancer.

I disagree with your statement. We adopt surveillance for a much longer period in a rare cancer than happens for a similar but common cancer, so I am not sure that your statement holds up.

Brian Whittle Con South Scotland
link

Your consensus statement paper states that

“In high-risk uveal melanomas, this surveillance should be performed by offering serial MRI imaging of the liver ... Serial ultrasound imaging may be considered as an alternative modality if the operator has experience of its use in uveal melanoma metastatic disease.”

In that instance, ultrasound operators are required to have specific experience relating to the disease. Given the rarity of the disease, which you have talked about, there cannot be that many experienced operators out there.

Dr Cauchi
link

I would agree with that. You might have picked up that that comment is in the statement because one of the members of the group felt strongly about it. From a Scottish perspective—and of course it is a Scottish statement—I think that all high-risk patients will get MRI scans because there are very few specialists who will have the expertise to be able to image the liver in a consistently accurate way that we would be happy with. However, there are excellent radiologists who are incredibly good at ultrasound. We have one in Glasgow. Can she image every one of our high-risk patients every six months? I do not think that she can. Therefore, the practicalities mean that we will almost certainly be doing MRI scans for most of our patients. There are a couple of very special individuals who have the skills to do the surveillance, but I do not think they have the time to be able to perform it on a wide scale.

Brian Whittle Con South Scotland
link

Have you had responses to the consensus statement from chief executives?

Dr Cauchi
link

They are digesting it at the moment—it is very recent. I have another hat—I am clinical director of ophthalmology in Greater Glasgow and Clyde. It has reached my desk because my director is asking, “What are we going to do about this statement?”, not realising that I wrote it.

Every health board is having to look at its numbers. In Scotland, it is okay, in a way, because we have been taking this approach in the west of Scotland for some time now, although obviously we were waiting for the official statement to come out. Out of 40 patients in Scotland, maybe 14 come from the Glasgow area and about half of those might be high risk, so we are talking about six or seven patients a year who are going to need six-monthly MRI scans. The number in the Highlands is lower, so the number who need the scans will be even lower. The two biggest centres—Lothian and NHS Greater Glasgow and Clyde—will obviously have the lion’s share. Even in those centres, the number of high-risk patients will be about 50 per cent of the number of new patients per year—and it is a rare disease.

However, we will now have quite an exercise, because all our current patient cohort will have to be offered that approach. We will have quite a headache over the coming months, but we will do it. That exercise will involve not just those six or seven a year for us in Glasgow or the 20 a year across Scotland, but our cohort of existing high-risk patients. We will have to have conversations that will be quite upsetting for some of our patients, to be honest. We will need to say, “You have a high-risk tumour. We have been doing liver ultrasounds, but the new recommendation is to do MRI scans”. We always base our decisions on the conversations that we have with our patients, and some patients will not want an MRI scan.

There will be an impact on the radiology departments across Scotland, but I do not think it will be a huge impact, in comparison with what would happen with more common cancers, for example. I suppose that the rarity is an advantage, in that we have lower numbers.

Maurice Corry Con West Scotland
link

On scanning and so on, can you explain why those who have low-risk uveal melanomas do not require ultrasound operators with experience in UMM disease, whereas those in the high-risk category do?

Dr Cauchi
link

It comes down to the risk benefit ratio again. Most of the people in Scotland who do ultrasound of livers have been trained to a level where they can pick up abnormalities in the liver. What that abnormality is can be open to interpretation. When an abnormality is picked up, we move on to MRI scanning if there is a concern.

You could say that we should offer everyone MRI scans. However, on the risk of getting metastatic disease—there is an appendix about this attached to my paper—if you have a stage 1 cancer, your risk is very low, and you have a 10-year survival rate of 94 per cent; and, if you have a 3A cancer, you have a 10-year survival rate of 60 per cent. I go back to my comments about MRI scanning, about the length of the test, the anxiety it induces in patients and so on. We felt that we drew the line at the correct place, where if someone has a low-risk melanoma, the easier, less anxiety-inducing test can be done. It is shorter; it is tolerated a lot better by patients; it is a quick and easy test; and it can be done closer to home.

It is about saying to the patient, “Yes, you can get the Rolls-Royce test, but if you are low risk the chances of picking something up are very low, and if we pick something up with the ultrasound we will move on to MRI scanning anyway.” It is about using the most appropriate test for the level of risk involved.

Maurice Corry Con West Scotland
link

Do you feel that there would be a greater risk of missing something even in a low-risk patient because the person doing the MRI would have less experience in operating the equipment?

Dr Cauchi
link

My colleague, Vikas Chadha, went to the Scottish clinical imaging network and spoke quite carefully with the people there about how their operators are trained in imaging livers and in ultrasound. We have been given very strong assurances that all their operators are trained to a level where they can detect abnormalities within a liver and that there should not be an problem.

There may always be issues, of course. For example, the operator may not be able to image the liver of a very obese patient completely, so there may be a substandard scan. Our group looked at that category. If a report came back saying, “We imaged the liver and it was clear, but we could not see the whole liver”, we would move on to an MRI scan. There are always caveats.

On the specific point about whether the radiographers or radiologists who do the scans are able to pick up abnormalities within the liver, we have been given assurances by SCIN that they can, and we have to have confidence in that.

Gail Ross SNP The Deputy Convener · Caithness, Sutherland and Ross
link

I hate talking about money when it comes to people’s health but, unfortunately, it is inevitable. Do you anticipate any additional costs or funding implications?

10:15

Dr Cauchi
link

There will be a cost implication, clearly, because we will be doing more MRI scans than we did previously. Being a clinical director, I know that there is a lot of pressure on radiology, and people forget about the reporting. It can take several months to get a report back after you get your scan, and that can be the most anxious time for patients, believe me. Given the numbers involved, I would hope that the extra cost could be absorbed in the current setup. I do not envisage needing more infrastructure or staff or any great changes from that point of view, but it will cost more money, undoubtedly.

Of course we always have to think of resource, because an MRI scan takes about an hour. That is an hour of scanning that you are taking away from the system, which has an impact on someone who is desperate for a scan. For example, someone who has a headache may wait several months to get an MRI scan. It is issues with the slots that are available within the system that prevent that patient from getting their scan. Like everything in health, you cannot just think about your own little bit; you have to think about the whole system.

Brian Whittle Con South Scotland
link

I understand that new NICE-accredited uveal melanoma guidelines are due to be published next year. Is there scope for the consensus statement to feed into the development of those?

Dr Cauchi
link

That is our hope, absolutely. The 2015 melanoma focus guidelines are due to be updated in 2020. Maybe that was another reason why there was a reluctance for the other groups to be involved. Perhaps they thought, “Why should we go through all the bother now when we are going to have to do it anyway in 2020?” Clearly, we were not prepared to wait for that time to come. I think that the consensus statement will have a big impact on those guidelines. Paul Nathan, who was a member of our group, was the chair of the previous guidelines group, and I suspect that he will be on the next group. I cannot imagine that that will not have an impact.

Recently, all the eye cancer groups in the UK met in Sheffield to compare our results. We presented our work at that meeting and I was pleasantly surprised to see that it was very well received. I expected that there would be negative feedback from my colleagues in England, because I think that it will have an impact on them in the long run and a lot of people would disagree with the use of MRI scans in high-risk patients. However, we have stolen a march on them and have said, “We need to get this problem resolved. If you do not want to engage, we will do it.” However, they are going to have to consider the issue in 2020.

The problem that we have here is that, if you just go on evidence, you would not scan anyone. I have spoken to clinical oncologists who have that opinion and have asked, “Why are you doing any of these scans? We do not agree with that.” The problem with a rare disease is that, if you are waiting for the evidence, the evidence may never come. We need to be pushing the boundaries, but at the same time we need to have a balance. If someone has a very high-risk cancer, it is very different to someone who has a very low-risk cancer. You cannot lump everything together; it would not be fair.

Gail Ross SNP The Deputy Convener · Caithness, Sutherland and Ross
link

You have touched on the position in the rest of the UK a few times now. If we wanted to understand this from an English or rest-of-UK position, who would you suggest that we could write to about that?

Dr Cauchi
link

Probably the most appropriate person would be Ayesha Ali, who is at the moment the commissioner for specialised services in England, just as our commissioners in Scotland are NSD. She is not a clinician, but she has overarching governance over the English centres. She is new in post, but I think that she would be the person to write to. I can give you her email address later.

Gail Ross SNP The Deputy Convener · Caithness, Sutherland and Ross
link

That would be helpful.

Maurice Corry Con West Scotland
link

I noticed that centres across the UK are well represented on your consensus statement group. However, two centres are missing: Liverpool and Southampton. Why is that?

Dr Cauchi
link

Southampton is not an ocular oncology centre, and we had plenty of representation from clinical oncologists.

Dr Cauchi
link

All the centres are centres of excellence. I have to say that I found some of the comments previously about one centre being better than another to be quite unsavoury—they are all centres of excellence.

We needed to get a group together. There was no representation from London and there was no representation from Liverpool.

Dr Cauchi
link

That is not necessarily London. That is clinical oncology. There is eye cancer and there is general cancer. The quick answer is that we did not want the group to become too cumbersome and we did not feel that we needed representation from all the centres.

Gail Ross SNP The Deputy Convener · Caithness, Sutherland and Ross
link

The submission from OcuMel UK—I apologise for you not having seen it in advance, but it came in quite late—is at odds with the evidence that you have given today. One paragraph says:

“We have not been consulted on this consensus statement and so we have not seen this document in depth. The patient involved in the consensus group made it clear they could give their personal view but not one representing patients.”

How do you respond to that, given the evidence that you have already given us?

Dr Cauchi
link

I do not agree with that. The patient was chosen because he was a member of OcuMel UK, because he was a patient with a condition and because he was a Scottish patient. Our purpose was to make recommendations in this current situation, and he was represented in that regard. We did not write to specific groups. We did not write to OcuMel UK, just as we did not write to a whole load of other groups. We did not write to all the centres. OcuMel UK is not the only patient focus group. That was not the remit of this consensus statement, it was to come to a conclusion on what we should offer our patients for surveillance.

I do not think we needed to consult OcuMel UK; I do not think we needed to consult, for example, Southampton. You need to draw a line as to where you are going to stop consulting people. We needed to get this statement out. The Public Petitions Committee has a robust process and I do not think that we needed to involve other people. This committee has been pretty thorough in addressing all the issues. OcuMel UK might have been unhappy that we did not consult it, but we did not feel that we had to consult it.

Regarding the patient representative, I am sure that he did not get exactly what he wanted from the group, nor did a lot of other people on the group. There were people on the group who did not want to recommend MRI scanning, but they were prepared to reach a compromise and to move forward on the issue. I am not surprised that there are unhappy parties, but this is better than the previous situation.

Gail Ross SNP The Deputy Convener · Caithness, Sutherland and Ross
link

Thank you very much. Do members have any comments or suggestions for action, reflecting on the evidence that we have heard?

Brian Whittle Con South Scotland
link

I was just having a quick read over what the petitioner was looking for. Based on what Dr Cauchi has said, it seems that, from the start of this process, significant, comprehensive and leading work has been done.

We have to be careful in our deliberation. It is not our responsibility to direct clinicians; our responsibility is to gather evidence. For me, the petitioner has been responsible for quite a significant shift in the way in which treatment is being given. I think that the only thing that is left for us to do is to get a response from the petitioner to the evidence that has been given today so that we can see whether they are satisfied with the work that has been done. I think that comprehensive work has been done here and that the petitioner has performed a great service. I am almost of a mind to suggest that we close the petition, but I would like to get a response from the petitioner first.

Gail Ross SNP The Deputy Convener · Caithness, Sutherland and Ross
link

Are there any other comments or suggestions?

Maurice Corry Con West Scotland
link

I agree with that, too. Brian Whittle is right, and I would like to hear what the petitioner has to say.

Gail Ross SNP The Deputy Convener · Caithness, Sutherland and Ross
link

The suggestion is that we agree to seek the views of the petitioner in response to the consensus statement and also the evidence today, and ask Dr Cauchi to respond in writing to the two late submissions that we have had, because there are some things in them that we want to hear his views on, and to write to us with guidance on the English position. Do we agree with that suggested action?

Members indicated agreement.

Gail Ross SNP The Deputy Convener · Caithness, Sutherland and Ross
link

Thank you for your evidence, Dr Cauchi. I suspend the meeting for a change of witnesses.

10:26 Meeting suspended.

10:33 On resuming—

  1. 09:00 Continued Petitions Petitions · 83
  2. 09:30 Continued Petitions Petitions · 59
  3. 10:15 Continued Petitions Petitions · 77

The type of each item (debate, statement, questions, members’ business and so on) and the times shown are worked out by this site from headings, the chair’s opening words and the Official Report’s running timestamps. They are not the Parliament’s own classification. Text: the Scottish Parliament Official Report.